clinical trial · NCT05541822
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Advanced Solid TumorsVabametkibLazertinib
brief summary
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
started
Jan 17, 2023
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
May 22, 2025
detailed description
This study will start with one cohort and it will be a parallel cohort expansion study.
official title
A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol